Wishing all a safe festive season and prosperous 2018.
One step back, two steps forward:
With the first SAE now behind us (holds now all lifted by FDA), all three clinical trials are back recruiting.
As each of the three trials was independently assessed, logic suggests (IMO) a derisking element to the common ptx200 compound.
That is, if another SAE were to occur ( probable in this area of experimental medicine) on one of the trials then one would think that only that particular trial may or may not need reassessment attention rather than the ‘all or nothing ‘ precursor case seen in 2017.
If the above is true (highly probable), then the ptx200 compound encompassed with the concurrent three trials is now, thanks to our professional team, derisked and two steps forward.
As this filters through to investors and profit taking subsides ( well done to those as well), we should see a gradual rise in SP beyond placement figure.
Note.... the above is in my opinion only, and not recommended as financial advice.
PTX Price at posting:
7.2¢ Sentiment: Buy Disclosure: Held
